Sundström E, Jonsson G
Eur J Pharmacol. 1986 Mar 18;122(2):275-8. doi: 10.1016/0014-2999(86)90113-5.
Pretreatment with the monoamine oxidase inhibitor pargyline or the catecholamine uptake blocker nomifensine both protected central catecholamine neurons against MPTP-induced neurotoxicity as monitored by analyzing catecholamine levels and [3H]mazindol binding. Post-treatment with the inhibitors showed that the administration of nomifensine could be delayed longer than that of pargyline in order to achieve a protective effect. The results are compatible with the view that the monoamine oxidase-catalyzed conversion of MPTP to a toxic metabolite MPP+ occurs mainly extraneuronally. MPP+ is subsequently taken up and accumulated selectively in catecholamine neurons, initiating degeneration.
通过分析儿茶酚胺水平和[3H]麦角乙脲结合情况监测发现,用单胺氧化酶抑制剂优降宁或儿茶酚胺摄取阻滞剂诺米芬辛进行预处理,均可保护中枢儿茶酚胺能神经元免受MPTP诱导的神经毒性。用这些抑制剂进行后处理表明,为达到保护作用,诺米芬辛的给药时间可比优降宁延迟更长。这些结果与以下观点相符:单胺氧化酶催化MPTP转化为有毒代谢物MPP+的过程主要发生在神经元外。随后,MPP+被摄取并选择性地积聚在儿茶酚胺能神经元中,引发变性。